The VIVO chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the VIVO chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The VIVO stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View VIVO Detailed Price Forecast - CNN Money||View VIVO Detailed Summary - Google Finance|
|View VIVO Detailed Summary - Yahoo! Finance||View VIVO Stock Research & Analysis - Zacks.com|
|View VIVO Trends & Analysis - Trade-Ideas||View VIVO Major Holders - Barrons|
|View VIVO Call Transcripts - NASDAQ||View VIVO Breaking News & Analysis - Seeking Alpha|
|View VIVO Annual Report - CompanySpotlight.com||View VIVO OTC Short Report - OTCShortReport.com|
|View VIVO Fundamentals - TradeKing||View VIVO SEC Filings - Bar Chart|
|View Historical Prices for VIVO - The WSJ||View Performance/Total Return for VIVO - Morningstar|
|View the Analyst Estimates for VIVO - MarketWatch||View the Earnings History for VIVO - CNBC|
|View the VIVO Earnings - StockMarketWatch||View VIVO Buy or Sell Recommendations - MacroAxis|
|View the VIVO Bullish Patterns - American Bulls||View VIVO Short Pain Metrics - ShortPainBot.com|
|View VIVO Stock Mentions - StockTwits||View VIVO Stock Mentions - PennyStockTweets|
|View VIVO Stock Mentions - Twitter||View VIVO Investment Forum News - Investor Hub|
|View VIVO Stock Mentions - Yahoo! Message Board||View VIVO Stock Mentions - Seeking Alpha|
|View Insider Transactions for VIVO - SECform4.com||View Insider Transactions for VIVO - Insider Cow|
|View VIVO Major Holdings Summary - CNBC||View Insider Disclosure for VIVO - OTC Markets|
|View Insider Transactions for VIVO - Yahoo! Finance||View Institutional Holdings for VIVO - NASDAQ|
|View VIVO Stock Insight & Charts - FinViz.com||View VIVO Investment Charts - StockCharts.com|
|View VIVO Stock Overview & Charts - BarChart||View VIVO User Generated Charts - Trading View|
Meridian Gets FDA Clearance for New Neonatal Saliva CMV Test
Posted on Thursday December 06, 2018
Meridian Bioscience, Inc. (VIVO) today announced that it has received FDA clearance for its new Alethia™ CMV Molecular Amplification Test (formerly, the illumigene brand). This assay is designed to specifically detect congenital Cytomegalovirus (cCMV) infection in newborns from an easy-to-collect saliva sample. Alethia CMV is the first qualitative test in a molecular amplification format, FDA-cleared for cCMV testing in newborns.
Is Meridian Bioscience Inc (NASDAQ:VIVO) A High Quality Stock To Own?
Posted on Monday December 03, 2018
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is for those who would like to learn about Return On
FDA approves Meridian Bioscience's test for herpes in newborns
Posted on Friday November 30, 2018
The U.S. Food and Drug Administration approved on Friday the first test - a diagnostic from Meridian Bioscience Inc - to help detect a type of herpes virus in newborns. Meridian's Alethia CMV Assay Test System detects cytomegalovirus (CMV) DNA from saliva swabs and won approval for use in babies younger than 21 days of age infected during pregnancy. Over half of adults have been infected with CMV by the age of 40, according to the Centers for Disease Control and Prevention.
Meridian Bioscience Inc (VIVO) Files 10-K for the Fiscal Year Ended on September 30, 2018
Posted on Thursday November 29, 2018
Meridian Bioscience Inc is an integrated life science company. The dividend yield of Meridian Bioscience Inc stocks is 2.69%. Meridian Bioscience Inc had annual average EBITDA growth of 2.00% over the past ten years.